AIM ImmunoTech (AIM) has announced encouraging initial results from its Phase 1b/2 trial, which is assessing the efficacy of combining Ampligen with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, Imfinzi, for treating advanced pancreatic cancer. The combination therapy was generally well-received, with no severe side effects or dose-limiting toxicities reported. The first group of patients has now completed the 6-month stability assessment, with two out of three participants maintaining stable disease.
AIM ImmunoTech specializes in immuno-pharmaceuticals, concentrating on research and development aimed at treating various cancers, immune disorders, and viral infections, including COVID-19. The company's flagship product, Ampligen, is a pioneering investigational drug that holds promise across multiple therapeutic areas.
